STOCK TITAN

First Wave BioPharma, Inc. - FWBI STOCK NEWS

Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.

First Wave BioPharma, Inc. (FWBI) is a leading biopharmaceutical company dedicated to developing non-systemic, recombinant protein therapies targeting gastrointestinal diseases and related conditions. Headquartered in New York, NY, with scientific operations based in Langlade, France, First Wave BioPharma aims to be at the forefront of innovative treatments in the biotech industry.

The company's flagship development program is MS1819 recombinant lipase, which is in advanced stages of development for treating exocrine pancreatic insufficiency (EPI). This condition often affects patients with cystic fibrosis and chronic pancreatitis, and MS1819 offers a promising alternative to current enzyme replacement therapies.

Besides MS1819, First Wave BioPharma is working diligently on early-stage research projects aimed at preventing hospital-acquired infections, further solidifying its focus on significant unmet medical needs.

In 2024, First Wave BioPharma plans to advance its gastrointestinal (GI) development pipeline significantly. The company expects to add the Phase 3 Latiglutenase celiac disease program and multiple Phase 2 clinical programs featuring Capeserod and Adrulipase. These initiatives are contingent upon the potential merger with ImmunogenX, a deal that could mark a year of substantial growth for the company.

Recent news highlights multiple clinical and development milestones anticipated in 2024, including the initiation of a Phase 3 clinical trial investigating latiglutenase in celiac disease. This trial is pivotal for the company's future, given the significant growth potential it represents in treating celiac disease effectively.

For detailed information and the latest updates, reach out to First Wave BioPharma at their Boca Raton office or through their media contact at Tiberend Strategic Advisors, Inc.

Rhea-AI Summary
First Wave BioPharma to present at 2023 BIO Investor Forum
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary
First Wave BioPharma to present at 2023 Roth Healthcare Opportunities Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences
-
Rhea-AI Summary
First Wave BioPharma to present at BIO Investor Forum
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.39%
Tags
conferences
Rhea-AI Summary
First Wave BioPharma announces agreements to exercise existing warrants at reduced price, expected to raise $4.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.78%
Tags
none
-
Rhea-AI Summary
First Wave BioPharma announces agreement with Sanofi to license and repurpose Capeserod for gastrointestinal indications. First Wave will receive an exclusive global license for Capeserod and will assume responsibility for all future clinical development. The agreement includes upfront payment, milestone payments, and royalties on net sales. Sanofi has conducted trials suggesting potential applications for Capeserod in multibillion-dollar markets. First Wave plans to initiate clinical trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.78%
Tags
none
-
Rhea-AI Summary
First Wave BioPharma to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.17%
Tags
conferences
Rhea-AI Summary
First Wave BioPharma, Inc. has announced the pricing of a public offering of 3,285,000 shares of its common stock and warrants to purchase up to 6,570,000 shares at a combined public offering price of $0.64 per share. Each share is being sold with two warrants, each to purchase one share. The warrants have an exercise price of $0.64 per share and expire five years after issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
First Wave BioPharma, Inc. announces topline results from Phase 2 SPAN clinical trial of adrulipase for exocrine pancreatic insufficiency in cystic fibrosis patients. The enhanced formulation showed improved safety and tolerability but likely did not meet the primary efficacy endpoint. Additional findings on primary and secondary endpoints to be reported in eight weeks. Plans to pursue an End-of-Phase 2 meeting with FDA for a registrational Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags

FAQ

What is the current stock price of First Wave BioPharma (FWBI)?

The current stock price of First Wave BioPharma (FWBI) is $2.96 as of May 17, 2024.

What is the market cap of First Wave BioPharma (FWBI)?

The market cap of First Wave BioPharma (FWBI) is approximately 6.0M.

What is First Wave BioPharma, Inc.'s core business?

First Wave BioPharma focuses on developing non-systemic, recombinant protein therapies for gastrointestinal diseases and related conditions.

What is MS1819 recombinant lipase?

MS1819 is First Wave BioPharma's lead development program, targeting exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

Where is First Wave BioPharma headquartered?

The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

What are the significant upcoming milestones for First Wave BioPharma in 2024?

Key milestones include the initiation of a Phase 3 clinical trial for latiglutenase in celiac disease and progression of Phase 2 clinical programs around Capeserod and Adrulipase.

How can I contact First Wave BioPharma for more information?

You can contact them at their Boca Raton office or through their media contact, Tiberend Strategic Advisors, Inc. David Schemelia at (609) 468-9325 or dschemelia@tiberend.com.

What potential growth opportunities are there for First Wave BioPharma?

The potential merger with ImmunogenX and the advancement of the GI development pipeline are expected to drive significant growth in 2024.

What research is First Wave BioPharma conducting besides MS1819?

The company is engaged in early-stage research for the prevention of hospital-acquired infections.

What is the significance of the Phase 3 latiglutenase program?

It represents a major advancement in treating celiac disease and could mark substantial growth for the company.

How has First Wave BioPharma performed in recent advancements?

The company has shown significant progress with major upcoming clinical trials and potential mergers, marking a promising future.

What impact does the merger with ImmunogenX have on First Wave BioPharma?

The merger is expected to facilitate the addition of advanced clinical programs, driving substantial growth and development in 2024.

First Wave BioPharma, Inc.

Nasdaq:FWBI

FWBI Rankings

FWBI Stock Data

5.99M
2.75M
5.66%
1.46%
2.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOCA RATON